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Abstract
The endocannabinoid (eCB) system can promote food intake by increasing odor detection
in mice. The eCB system is over-active in human obesity. Our aim is to measure circulating
eCB concentrations and olfactory capacity in a human sample that includes people with
obesity and explore the possible interaction between olfaction, obesity and the eCB system.
The study sample was made up of 161 females with five groups of body mass index sub-
categories ranging from under-weight to morbidly obese. We assessed olfactory capacity
with the “Sniffin´Sticks” test, which measures olfactory threshold-discrimination-identifica-
tion (TDI) capacity. We measured plasma concentrations of the eCBs 2-arachidonoylgly-
cerol (2-AG) and N-arachidonoylethanolamine or anandamide (AEA), and several eCB-
related compounds, 2-acylglycerols and N-acylethanolamines. 2-AG and other 2-acylgly-
cerols fasting plasma circulating plasma concentrations were higher in obese and morbidly
obese subjects. AEA and other N-acylethanolamine circulating concentrations were lower
in under-weight subjects. Olfactory TDI scores were lower in obese and morbidly obese
subjects. Lower TDI scores were independently associated with higher 2-AG fasting plasma
circulating concentrations, higher %body fat, and higher body mass index, after controlling
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for age, smoking, menstruation, and use of contraceptives. Our results show that obese
subjects have a lower olfactory capacity than non-obese ones and that elevated fasting
plasma circulating 2-AG concentrations in obesity are linked to a lower olfactory capacity. In
agreement with previous studies we show that eCBs AEA and 2-AG, and their respective
congeners have a distinct profile in relation to body mass index. The present report is the
first study in humans in which olfactory capacity and circulating eCB concentrations have
been measured in the same subjects.
Introduction
Food intake and body weight regulation are processes highly controlled by brain neural sys-
tems that integrate a multitude of signals and hormones relaying information about both the
internal state and the environment [1]. The high prevalence of obesity in modern industrialized
societies [2] has been linked to changes in environmental factors together with a sedentary life-
style. A widespread availability of energy-dense and highly palatable foods and the increased
presence of powerful food cues override homeostatic satiety signals by influencing cortico-lim-
bic brain areas concerned with learning, memory, reward, and emotion [3]. One of such areas
is the olfactory system. The sense of smell is essential for human flavor perception [4] and it
contributes to our food choices and eating behavior by participating in the hedonic evaluation
of foods [5,6]. Olfaction influences both appetite and satiety in humans [7]. A high reactivity to
olfactory food cues has been observed in over-weight children [8]. Food-related odors activate
brain reward circuits during hunger, and the more active areas are different in obese and nor-
mal-weight subjects [9]. Converging evidence also suggests that the olfactory system is inti-
mately linked to neural systems that regulate food intake by acting as a sensor of the metabolic
state [10]. This is supported by the presence in the olfactory bulb of receptors of several hor-
mones and neuromodulators that regulate food intake, among them: insulin, leptin, ghrelin,
orexin or endocannabinoids [10]. It has been recently demonstrated that the endocannabinoid
(eCB) system, a key homeostatic and hedonic modulator of food intake [11], promotes eating
in fasted mice by enhancing the sense of smell [12]. This important finding raises issues regard-
ing the role of odor perception in eating behavior and obesity. As reviewed by Kirkham [13],
exogenous and endogenous cannabinoids stimulate food intake by increasing the motivation
to eat and by amplifying the palatability, or orosensory reward of food. Administration of the
cannabinoid delta-9-tetrahidrocannabinol (THC) improves taste and smell and the enjoyment
of food in cancer patients [14]. In obesity, the central and peripheral eCB system becomes
over-active [15,16]. Peripheral signals that regulate food intake like insulin, leptin or ghrelin
that interact with the eCB system and which are also altered in obesity [17] seem to modulate
olfactory sensitivity[10,18–20].
Olfactory capacity decreases with the increase in body mass index [21]. The reason is not
well understood but it may be related to cognitive deficits associated to obesity [22], since olfac-
tory capacity can predict cognitive decline [23]. Olfaction is processed in the limbic area of the
brain where emotion and memory are stored. Differently to other senses that need the thala-
mus relay, the olfactory sense is unique since it is the only sense that has a direct connection to
the higher cognitive centers of the brain. The olfactory bulb has direct connections to the piri-
form cortex. The piriform cortex and the amygdala both project to the orbitofrontal cortex
(OFC) which with the amygdala is involved in emotion and associative learning, and to the
entorhinal/hippocampal system which is involved in long-term memory including episodic
Olfaction, Obesity and the Endocannabinoid System
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memory [24–27]. Olfaction has two components, detection and perception. First, the odorants
are detected on the nasal cavity by specific receptor cells. Second, the information is sent and
processed in the brain. Perception is much more complex than detection because it involves
memory and emotion in the identification of an odor [4,26].
Our aim is to measure circulating eCB concentrations and olfactory capacity in a human
sample that includes people with obesity and explore the possible interaction between olfac-
tion, obesity and the eCB system. In the present report we show that obese subjects have a
reduced olfactory capacity and that higher eCB fasting plasma circulating concentrations in
obesity are associated to a reduced olfactory capacity.
Methods
Subjects
The study sample was made up of 161 females (aged 18–65 years) with body mass indices
(BMI) ranging from under-weight to morbid obesity. The characteristics of the study subjects
are presented in Table 1. Seven centers, all involved in the CIBERObn (Spanish Biomedical
Research Centre in Physiopathology of Obesity and Nutrition, www.ciberobn.com), partici-
pated. Only women were selected for this study. The population of subjects from the present
study comes from a larger clinical cohort for the study of eating disorders in women. Obese
participants (BMI>30 Kg/m2) were patients who had been consecutively referred to the clinics
mentioned above. Recruitment of the non-obese participants (BMI<30 Kg/m2) took place by
means of word-of-mouth and advertisements at local universities. Non-obese participants were
from the same catchment area as the clinical groups. The selection was based on BMI. Exclu-
sion criteria included: a) being male, b) a history of chronic medical illness, c) the use of psy-
choactive medication and drugs, d) Age under 18 or over 65 years. Subjects diagnosed with
eating disorders, such as anorexia, bulimia, or binge eating disorder, were excluded from this
sample. Enrolment in the study was between January 2010 and September 2012. All partici-
pants gave written and signed informed consent, the study was conducted according to the
Declaration of Helsinki and the Ethics Committee of all the institutions involved [Comissió
Deontológica de la Universitat Jaume I, Subcomisión Clínica del Hospital Universitario “Vir-
gen de la Victoria”, Málaga, Comite Etic de Investigacio Clinica Hospital Universitari de
Girona Doctor Josep Trueta (048/10), Comite Etico de Investigacion Clinica del Consorci Mar
Parc de Salut de Barcelona-Parc de Salut Mar (2010/3914/I), Comité de Etica de la Investiga-
ción Universidad de Navarra (110/2010) and Comité Etico de Investigación Clínica del Hospi-
tal Universitari de Bellvitge (307/06)] approved the study.
Anthropometry
For the purpose of the study, the following measures were considered: height (m), weight (kg),
BMI (kg/m2), and %body fat. Body composition was assessed using a Tanita Multi-Frequency
Body Composition Analyzer MC-180MA (Tanita Corp., Tokyo, Japan). Tanita uses the non-
invasive technique of bioelectrical impedance analysis (BIA) that predicts from a series of equa-
tions total body water content and free fat mass, from which fat mass can be calculated.
Lipid profile
EDTAK2 plasma glucose, total cholesterol (Total-C), and triglycerides were determined by
enzymatic methods, high-density lipoprotein cholesterol (HDL-C) by an accelerator selective
detergent method in a PENTRA-400 autoanalyzer (ABX-HORIBA Diagnostics, Montpellier,
Olfaction, Obesity and the Endocannabinoid System
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France). Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald equa-
tion whenever triglycerides were<300 mg/dL.
Quantification of eCBs and related compounds
The eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were quantified in plasma of
participants. In addition, the following eCB chemically related compounds, N-acylethanola-
mines and 2-acylglycerols, were quantified in plasma: palmitoylethanolamide (PEA), linoleoy-
lethanolamide (LEA), oleoylethanolamide (OEA), docosahexaenoylethanolamide (DHEA),
2-linoleoylglycerol (2-LG), and 2-oleoylglycerol (2-OG). Blood samples were collected from
subjects between 8 and 9 am after at least 12 hours of fasting, and on the same day that the
olfactory tests were undertaken. Blood was collected in 10 mL K2E 18.0 mg (EDTA) BD Vacu-
tainer tubes. Blood tubes were centrifuged at 1700 g at 4°C for 15 min. Plasma was separated,
distributed in aliquots, and stored at -80°C until analysis. The extraction and analysis of plasma
eCBs and eCB-related compounds was performed by a validated method previously described
[28]. Briefly, aliquots of 0.5 mL of plasma of the study subjects were transferred to 12 mL glass
tubes, spiked with isotope-labeled internal standards, diluted with 0.1M ammonium acetate
buffer (pH 4.0), and extracted with tert-butyl methyl ether. The organic layers were separated
into clean 12mL glass tubes and placed in a water bath (29°C) under a stream of nitrogen. The
dry organic extracts were reconstituted in 100 μL of a mixture water: acetonitrile (10:90, v/v)
with 0.1% formic acid (v/v) and transferred to HPLC vials. Twenty μL were injected into the
LC/MS-MS system. An Agilent 6410 triple quadrupole (Agilent Technologies, Wilmington,
DE) coupled to a chromatographic system consisting in a 1200 series binary pump, a column
oven and a cooled autosampler (4°C) were used. Chromatographic separation was carried out
by gradient chromatography with a Waters C18-CSH column (3.1 x 100 mm, 1.8 μm particle
size) maintained at 40°C with a mobile phase flow rate of 0.4 mL/min. The composition of the
mobile phase was: A: 0.1% (v/v) formic acid in water; B: 0.1% (v/v) formic acid in acetonitrile.
The electrospray ion source was set on the positive ionization mode. The mass spectrometry
detection was done by single reaction monitoring (SRM). Quantification was done by isotope
dilution. Isotope-labeled internal standards were obtained from Cayman Chemical (Ann
Arbor, MI) and solvents were fromMerck (Darmstadt, Germany). 2-acylglycerols were
Table 1. Characteristics of the study subjects.
UW (n = 18) NW (n = 70) OW (n = 13) OB (n = 26) MO (n = 34)
BMI<19 kg/m2 19BMI<25 kg/m2 25BMI<30 kg/m2 30BMI<40 kg/m2 BMI40 kg/m2
Age (yrs) 24.0 (7.45) 27.4 (7.36) 33.4 (7.64) 47.3 (11.1) 43.5 (11.2)
Height (cm) 164 (7.99) 166 (6.40) 162 (4.11) 161 (6.27) 161 (7.36)
Weight (Kg) 48.9 (5.20) 59.9 (6.31) 70.9 (4.67) 92.0 (8.44) 122 (17.8)
BMI (Kg/m2) 18.1 (0.64) 21.7 (1.62) 26.9 (0.94) 35.5 (2.53) 46.7 (5.10
% fat mass 18.7 (4.06) 27.0 (4.48) 33.6 (3.59) 42.1 (6.14) 46.4 (4.19)
LDL-C (mg/dL) 84.5 (28.9) 92.7 (23.8) 106 (26.1) 116 (33.5) 107 (24.7)
HDL-C (mg/dL) 55.4 (16.0) 58.1 (10.3) 58.5 (16.0) 47.6 (7.39) 43.8 (8.98)
Total-C (mg/dL) 154 (43.1) 166 (31.0) 180 (36.8) 187 (37.8) 179 (33.7)
Triglycerides (mg/dL) 65.9 (25.9) 77.4 (29.4) 84.9 (44.6) 138 (85.5) 148 (63.3)
Glucose (mg/dL) 86.6 (9.34) 86.0 (19.8) 87.6 (4.14) 102 (25.5) 101 (18.4)
Data are mean (standard deviation), under-weight (UW), normal-weight (NW), over-weight (OW), obese (OB), morbidly obese (MO), body mass index
(BMI), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (Total-C)
doi:10.1371/journal.pone.0148734.t001
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reported as the sum of isomer 1 and isomer 2 due to the instability of isomer 2 to isomerization.
Quantification was done by isotope dilution.
Olfactory Capacity tests
Olfactory capacity was assessed by the “Sniffin´Sticks” test (Burghart Messtechnik GmBh,
Wedel, Germany), which evaluates chemosensory performance based on pen-like odor-dis-
pensing devices. The test has been previously described and validated [29] and it is deemed
suitable for the routine clinical assessment of olfactory performance. It is made up of three sub-
tests: odor threshold (OT), odor discrimination (OD), and odor identification (OI). OT is the
lowest concentration of a certain odor compound that is perceivable by the human sense of
smell. OD and OI show the capacity to differentiate and identify odorants, respectively. OD
and OI are more related to cognitive aspects of olfaction, while OT is more sensorial [30]. OT
was assessed with n-butanol, while OD and OI were assessed with sixteen common fragrances,
such as peppermint, orange, leather, cinnamon, banana, garlic, lemon, rose, coffee, apple,
clove, pineapple, aniseed and fish [29]. Subjects were assessed individually in a well-ventilated
room and they wore eye masks to perform the test. Subjects were requested not to smoke, chew
gum or having eaten any products during the previous one hour at the start of the test. The
tests were performed in the time period after breakfast and before lunch and on the same day
that blood was collected for eCB analysis. A trained researcher carried out the tests in the fol-
lowing order: OT, OD and OI.
Olfactory threshold (OT) test. Using a triple-forced choice paradigm, detection thresh-
olds were measured by employing a single staircase method. Three pens were presented in
a randomized order, two pens contained odorless samples, and the third contained an odor-
ant sample at a particular dilution. A total of 16 odor concentrations were tested. The task of
the subject was to indicate which pen contained the odorant. Concentration of the odorant
was augmented if the subject chose an odorless pen and reduced if the correct pen was recog-
nized twice, which triggered a reversal of the staircase. The mean of the last four staircase
reversal points of a total of seven reversals was used as the threshold estimate. The range of
this score is from 0 to 16 points. The higher is the score the higher is olfactory threshold
capacity.
Olfactory discrimination (OD) test. The subjects were asked to discriminate between 16
triplets of odors. In each group two odors were identical and one odor was different and the
task was to recognize the pen in which the odor was different. The total score was the sum of
correct responses, which can range from 0 to 16 points. The higher is the score the higher is
olfactory discrimination capacity.
Olfactory identification (OI) test. A pen with an odor was presented to the subject. Sub-
jects were asked to identify the odor, by choosing it in a card from a list of four descriptors,
only one of which correctly identified the odor. For this purpose the eye mask was removed
(only for reading the card). The total score was the sum of correct responses, which can range
from 0 to 16 points. The higher is the score the higher is olfactory identification capacity.
Threshold-discrimination-identification (TDI) score. The sum of the scores from the
three subtests results in the composite olfactory threshold-discrimination-identification
(TDI) score, which can range from 0 to 48 points. The higher is the score the higher is olfac-
tory capacity. TDI declines with age, the strongest decrease is observed in individuals >55
years [31]. Normosmia, or normal olfactory function is defined for TDI scores higher than
30.3 points, hyposmia, or decrease in olfactory capacity is defined for TDI scores lower than
30.3, and anosmia, or functional loss of olfactory capacity is defined for TDI scores lower
than 16.5.
Olfaction, Obesity and the Endocannabinoid System
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Statistical analysis
Characteristics of the five BMI sample groups are presented by the mean and the standard devi-
ation. Boxplots (Tukey) were generated with software GraphPad Prism 5. Statistical analysis
was performed with the software packages SPSS (version 18) and R (version 3.2.1). ANCOVA
models were employed to compare the BMI groups with respect to eCB concentrations and
olfactory scores adjusting for age. In the framework of this model the Tukey test was used for
the post-hoc pairwise comparisons. The correlations between the olfactory variables, on one
hand, and the other study variables, on the other hand, were estimated using Pearson's correla-
tion coefficient. In addition, the association of TDI scores with BMI, %body fat and 2-AG was
studied by means of ANCOVAmodels that controlled for age, smoking (yes/no), menstruation
(normal/irregular/menopause), and the use of contraceptives (yes/no) as all these variables
could affect olfactory capacity. Both the estimated parameter (B) of each variable of interest and
the coefficient of determination (R2), which represents the percentage of variability of TDI
explained by the models, are presented.
Results
Differences in eCB concentrations between BMI groups
The concentrations of eCBs and related compounds of each BMI sample group are presented
in Fig 1. Plasma concentrations of 2-monoacylglycerols 2-AG, 2-LG and 2-OG were signifi-
cantly elevated in obese and morbidly obese subjects, while plasma concentrations of N-acy-
lethanolamines AEA, LEA and PEA were significantly lower in under-weight subjects.
Olfactory capacity, BMI and eCBs
Olfactory scores of each BMI sample group are presented in Fig 2. TDI scores are shown in
relation to the TDI score of<30.3, typically used in clinics for hyposmia diagnostic [31]. TDI
scores were significantly lower in obese and morbidly obese subjects. With respect to the olfac-
tory sub-tests OT and OI scores were significantly lower in obese subjects but not in morbidly
obese subjects.
Next, we assessed the correlation of olfactory scores with the other study variables. TDI
scores negatively correlated with age, BMI, %body fat, and fasting plasma concentrations of
2-AG, 2-LG, 2-OG, triglycerides and glucose (Table 2). We note that triglycerides and glucose
did not correlate with OT.
In addition to age olfaction may be affected by other factors such as smoking. status. Estro-
gen levels may also affect olfaction. Thus, menopause, normal or irregular menstruation and
the use of contraceptives are possible cofounding factors. The mean olfactory scores of subjects
categorized with these cofounding factors are shown in Table 3.
We studied the association of TDI with the other study variables by means of ANCOVA
models that controlled for age, smoking, menstruation, and the use of contraceptives. We
found that lower TDI scores were independently associated with higher BMI [B = -0.09 (-0.17,-
0.01; 95% CI), p = 0.026, R2model = 0.16], higher %body fat [B = -9.97 (-18.0,-1.92; 95% CI),
p = 0.016, R2model = 0.17], and higher 2-AG fasting plasma circulating concentrations [B =
-0.83 (-1.45,-0.20; 95% CI), p = 0.010, R2model = 0.17]. In this sample olfactory scores negatively
correlated with age and BMI (Table 2). Although the statistical adjustment for age is valid we
also evaluated the olfactory scores and 2-AG concentrations in a sub-sample of individuals that
were selected to have homogeneity in the age of BMI groups. A subsample of 54 individuals
was selected from the study sample with ages comprised between 30–45 years old (Table 4).
Olfaction, Obesity and the Endocannabinoid System
PLOSONE | DOI:10.1371/journal.pone.0148734 February 5, 2016 6 / 15
Fig 1. Endocannabinoid and related compounds plasma concentrations. Box plots of plasma concentrations of 2-arachidonoyl glycerol (A),
anandamide (B), 2-linoleoylglycerol (C), docosahexaenoylethanolamide (D), 2-oleoylglycerol (E), oleoylethanolamide (F), linoleoylethanolamide (G), and
palmitoylethanolamide (H) of subjects from each of the body mass index (BMI) sub-groups. The median is represented as a line within the box plot and the
mean is represented as a + sign. Significant differences (p<0.05) of endocannabinoids and related compounds concentrations between BMI subgroups are
represented by asterisks (*).
doi:10.1371/journal.pone.0148734.g001
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Fig 2. Olfactory scores. Box plots of odor threshold-discrimination-identification (TDI) scores (A), odor threshold scores (B), odor discrimination scores (C),
and odor identification scores (D) of subjects from each of the body mass index (BMI) sub-groups. The median is represented as a line within the box plot and
the mean is represented as a + sign. Discontinuous line in (A) represents the TDI score of 30.3 that separates normosmia from hyposmia. Significant
differences (p<0.05) of olfactory scores between BMI sub-groups are represented asterisks (*).
doi:10.1371/journal.pone.0148734.g002
Table 2. Olfactory scores correlations.
Odor threshold Odor discrimination Odor identiﬁcation TDI
Age (yrs) r = -0.16, p = 0.049 r = -0.21, p = 0.008 r = -0.25, p = 0.002 r = -0.29, p<0.001
BMI (Kg/m2) r = -0.17, p = 0.030 r = -0.20, p = 0.011 r = -0.31, p<0.001 r = -0.32, p<0.001
%body fat r = -0.21, p = 0.009 r = -0.23, p = 0.004 r = -0.27, p = 0.001 r = -0.33, p<0.001
2-AG (ng/mL) r = -0.23, p = 0.004 r = -0.23, p = 0.004 r = -0.23, p = 0.003 r = -0.33, p<0.001
2-LG (ng/mL) r = -0.15, p = 0.063 r = -0.20, p = 0.015 r = -0.20, p = 0.017 r = -0.26, p = 0.001
2-OG (ng/mL) r = -0.14, p = 0.080 r = -0.18, p = 0.025 r = -0.18, p = 0.024 r = -0.24, p = 0.003
Triglycerides (mg/dL) r = -0.10, p = 0.209 r = -0.15, p = 0.065 r = -0.18, p = 0.025 r = -0.21, p = 0.010
Glucose (mg/dL) r = -0.08, p = 0.307 r = -0.19; p = 0.023 r = -0.21; p = 0.009 r = -0.23; p = 0.005
Odor threshold-discrimination-identiﬁcation score (TDI), body mass index (BMI), 2-arachidonoylglycerol (2-AG), 2-linoleoylglycerol (2-LG), 2-oleoylglycerol
(2-OG)
doi:10.1371/journal.pone.0148734.t002
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Results on Table 4 confirm that in two different BMI groups homogeneous by age, obese
subjects (BMI 30 Kg/m2) have a lower olfactory capacity and higher 2-AG fasting plasma cir-
culating concentrations than non-obese subjects. The BMI sub-categories within these groups
were not considered for this analysis to not lose statistical power.
Discussion
Results of the present report show that obese subjects have a lower olfactory capacity than non-
obese ones and that higher 2-AG fasting plasma circulating concentrations are also linked to a
lower olfactory capacity. In agreement with previous studies we show that eCBs AEA and
2-AG, and their respective congeners have a distinct profile in relation to body mass index. The
study sample comprised women with a wide range of BMI from under-weight to morbidly
obese. Age is the most important factor that affects olfaction. We note that the mean age of the
groups was lower for lower BMI categories and higher for higher BMI categories. These differ-
ences were taken into account in the statistical analysis. In the comparison between eCB con-
centrations and olfactory scores between BMI groups the statistical analysis were adjusted for
age. In the ANCOVA models the associations between BMI, %body fat, 2-AG concentrations
and TDI were adjusted by age and other possible cofounding factors that included smoking sta-
tus, normal or irregular menstruation, menopause and use of oral contraceptives. Our findings
were confirmed in a sub-sample of individuals aged 30–45 years old in which the age of two
different BMI groups, obese and non-obese was homogeneous.
Table 3. Olfactory scores of study subjects in relation to different cofounding factors.
TDI Odor threshold Odor discrimination Odor identiﬁcation
Normal menstruation 32.1 (4.02) 6.62 (2.22) 12.7 (1.84) 12.8 (1.82)
Irregular menstruation 30.7 (4.86) 6.08 (1.90) 12.4 (2.80) 12.2 (2.09)
Menopause 28.3 (3.93) 5.47 (1.51) 11.8 (2.25) 11.1 (2.55)
Do not use oral contraceptives 31.2 (4.63) 6.38 (2.27) 12.4 (2.18) 12.4 (2.14)
Use of oral contraceptives 31.5 (3.29) 6.21 (1.56) 12.7 (1.61) 12.6 (1.75)
Non-Smokers 31.3 (4.29) 6.24 (1.70) 12.4 (2.14) 12.6 (1.90)
Smokers 31.9 (4.18) 6.33 (2.62) 12.9 (1.70) 12.6 (2.05)
Data are mean (standard deviation); Odor threshold-discrimination-identiﬁcation (TDI) score
doi:10.1371/journal.pone.0148734.t003
Table 4. OIfactory scores and endocannabinoid concentrations in a subsample of individuals aged between 30–45 years old.
Non-obese (n = 30) Obese (n = 24) p
BMI < 30 kg/m2 BMI  30 Kg/m2
Age (yrs) 35.0 (3.97) 36.5 (4.56) 0.211
BMI (Kg/m2) 22.6 (7.99) 41.7 (6.50) <0.001
% body fat 27.4 (5.51) 44.6 (5.47) <0.001
2-AG (ng/mL) 1.41 (0.79) 3.05 (1.41) <0.001
TDI 33.7 (4.67) 29.6 (3.81) 0.001
Odor threshold 7.31 (2.85) 5.92 (1.70) 0.039
Odor discrimination 13.3 (1.82) 11.5 (2.19) 0.002
Odor identiﬁcation 13.2 (1.79) 12.2 (1.74) 0.053
Data are mean (standard deviation); Odor threshold-discrimination-identiﬁcation (TDI) score; Unpaired t-test (p)
doi:10.1371/journal.pone.0148734.t004
Olfaction, Obesity and the Endocannabinoid System
PLOSONE | DOI:10.1371/journal.pone.0148734 February 5, 2016 9 / 15
Olfaction seems to be affected by the nutritional status [10]. We performed the olfactory
tests in a relatively low hunger state, which is the time period between breakfast and lunch and
subjects could not have eaten at the previous hour of the start of the test. A high hunger state
increases olfactory sensitivity [32,33] and food palatability [32]. It is noteworthy that studies
have reported differences in olfactory threshold under hunger or satiety between neutral and
food odors [33] [34] or in the pleasantness of odors [34]. Interestingly, in a recent study it
was reported that obese subjects have a greater sensitivity and preference for the odor of
chocolate than non-obese subjects [35]. This is in contrast to our results in which we used the
neutral odorant n-butanol for the OT test. These differences are possibly due to the different
hedonic value of odors, especially the food-related ones. For instance, it also has been reported
that obese subjects perceive the odor of black pepper oil as less pleasant than non-obese sub-
jects [36].
Obese and morbidly subjects had a lower olfactory capacity than normal-weight subjects.
OI and OT were the olfactory domains more affected by an increase of BMI. In this study we
did not observe a worse olfactory capacity in morbid obese vs obese subjects as reported previ-
ously [21]. The decrease in olfactory capacity in obesity may be explained by a loss of olfactory
neurons due to a high fat diet, as it has been observed in mice [37]. It is noteworthy that in
mice models of diet-induced obesity, the levels of eCBs, the expression of eCB biosynthetic and
inactivating enzymes and the expression of eCB receptors are altered in the hippocampus [38]
[39], a region that participates in the formation of odor memories, mediates hedonic aspects of
eating, and influences cognitive processes. It has been hypothesized that a Western diet rich in
saturated fat and sugar leads to obesity due to neurobiological changes in the hippocampus
that affect cognitive function, specifically in memory and learning functions necessary for the
inhibitory control in response to food cues [40]. Cognitive functions related to olfaction are
also relevant in humans with regard to learning a flavor during ingestion [6]. Finally, it has
been reported previously that 2-AG circulating levels inversely correlate with cognitive flexibil-
ity [41].
The over-activation of the eCB system in obesity may lead to changes in olfactory percep-
tion and eating behavior. A previous report has shown that cannabinoids decrease odor thresh-
old and stimulate food intake in fasted mice by means of olfactory processes [12]. In the
present study, we found that a reduced olfactory capacity is related to high 2-AG fasting plasma
circulating concentrations and high BMI. Permanent high eCB concentrations associated to
obesity may lead to adaptive responses such as resistance to eCB signaling. For instance, a
chronic exposure to a high-fat, palatable diet in mice has been shown to decrease the expres-
sion of the CB1 receptor in the nucleus accumbens shell, the hedonic “hotspot”, and in the hip-
pocampus [42]. An alteration of reward pathways has been postulated as one possible cause for
obesity [43]. In this work we did not quantify food enjoyment, but a loss of flavor due to a
reduced olfactory capacity could shift the diet to eating more high caloric and palatable foods
[44]. In addition, satiety mechanisms that rely on the olfactory system, such as olfactory sen-
sory-specific satiety may be affected [45].
2-AG circulating concentrations, but not AEA ones, were inversely associated with olfactory
capacity. 2-AG was also the eCB associated with obesity. Our results are in agreement with pre-
vious studies that relate 2-AG but not AEA with %visceral fat and dyslipidemia [46–48]. Nota-
bly, olfactory capacity was also inversely associated to %body fat. Although 2-AG and AEA are
both agonists of CB1 receptors and they share the backbone of arachidonic acid in their struc-
ture they have different biosynthetic and degradation routes [49], which suggest they play a dif-
ferent modulatory role. With regard to the modulation of food intake by eCBs, an elegant
experiment of Monteleone et. al. [50] showed an increase in 2-AG concentrations but not
those of AEA associated to hedonic eating. We also note that although unrelated to differences
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in olfactory capacity, AEA concentrations were lower in healthy under-weight subjects. This is
opposite to the eCB profile in anorexia, as anorexic subjects have elevated concentrations of
AEA and unchanged concentrations of 2-AG [51]. Circulating concentrations of eCB-related
compounds mimicked the differential trend of eCBs AEA and 2-AG with regard to the BMI of
the participants. The collective low concentrations of N-acylethanolamines AEA, LEA, and
PEA in under-weight subjects and the collective high concentrations of 2-acylglycerols 2-AG,
2-LG and 2-OG in obese and morbidly obese subjects suggest an up-regulation and/or down-
regulation of the enzymes responsible for eCB biosynthesis and inactivation. With the excep-
tion of AEA and 2-AG, the rest of N-acylethanolamines and 2-acylglycerols do not bind to
CB1 or CB2 receptors and have different molecular targets. However, they are biosynthesized
and degraded by the same enzymes that metabolize AEA and 2-AG respectively [52]. In obese
subjects, an up-regulation of diacylglycerol lipase α (DAGLα), the enzyme that biosynthesizes
2-AG and the other 2-acylglycerols, and a down-regulation of monoacylglycerol lipase
(MAGL), the enzyme that degrades 2-AG and other 2-acylglycerols, have been reported [53].
Studies also have reported that a down-regulation of fatty acid amide hydrolase (FAAH), the
enzyme that degrades AEA and other N-acylethanolamines, is associated to obesity [15,53,54].
In our study, however, we did not observe significant differences in N-acylethanolamine con-
centrations in obese subjects. ECB-related compounds or cannabimimetics may also enhance
the activity of AEA and 2-AG by competing with inactivating enzymes or carriers (entourage
effect) [55]. Cannabimimetics can bind to different receptors so they can have different or
opposite actions to eCBs. These actions are mediated through peripheral receptors. The most
studied of the cannabimimetic compounds are OEA, that has anorectic effects, and PEA that
has anti-inflammatory effects. Both actions are mediated by activation of peripheral peroxi-
some proliferator-activated receptor-alpha (PPARα), which is highly expressed in metaboli-
cally active tissues [56]. In obesity, the biosynthesis of N-acylethanolamines PEA and OEA
may also be dysregulated in peripheral tissues such as adipose tissue and pancreas [57]. PEA is
also the cannabimimetic compound more abundant in adipocytes [58]. OEA, PEA, LEA, 2-OG
and other 2-acylglycerols are possible endogenous agonists of GPR119, which acts as a fat sen-
sor. The activation of this receptor stimulates the release of intestinal glucagon-like peptide 1
(GLP-1), an incretin involved in glucose homeostasis and satiation [59–61]. 2-acylglycerols
originate from fat digestion in the intestinal lumen, from the hydrolysis of triacylglycerol [62].
The high plasma concentrations of 2-acylglycerols 2-LG and 2-OG that we found in obese sub-
jects may be related to the high triglyceride plasma concentrations also found in obese subjects.
In summary we have shown that obese subjects have a lower olfactory capacity than non-
obese ones and that high 2-AG fasting plasma concentrations are linked to a lower olfactory
capacity. In agreement with previous studies we showed that elevated 2-AG concentrations
were linked to high BMI and obesity. Obese subjects had deficits in both odor threshold (OT)
and odor identification (OI) capacity. A decrease in OI or in OD capacity may be related to
cognitive deficits associated to obesity. Lower AEA and other NAE concentrations were associ-
ated to low BMI, while high 2-AG and other 2-MG concentrations were associated to high
BMI, suggesting a possible differential up-regulation or down-regulation of the enzymes that
biosynthesize and inactivate NAE and 2-MG in these two extreme weight categories.
We cannot yet link a lower olfactory capacity as a result of a dysregulated eCB system in
obesity since this is a cross-over study, and a cause-effect cannot be inferred from these data.
This study has also other limitations that need to be addressed in future studies. First, the con-
clusions cannot be applied to the general population, and only to women. These findings
should be replicated in men. Second, the relationship between plasma and brain eCB concen-
trations is unknown. We make the assumption that peripheral eCB concentrations are bio-
markers of the state of the brain eCB system. The origin of plasma eCB is unknown and they
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may be originated in part from organ spillover. Third, eCB concentrations were measured after
12 hours fasting conditions and olfactory tests were performed after at least one hour of fast in
the same morning. Despite these time differences we think our results are still valid since they
were obtained in separate standardized conditions for all subjects and we were able to find sig-
nificant differences between groups in both olfactory capacity and eCB concentrations. A
simultaneous measure in time of plasma eCBs and olfactory performance is also not possible to
obtain since it takes at least half an hour for a subject to undertake the olfactory test. And last,
future studies should also include food-related odors due to their known effects on olfactory
thresholds, and for the study of brain reward circuits and food enjoyment.
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